摘要
目的观察单用表阿霉素（EPI）聚乳酸（PLA）缓释微球（MS）及联合游离表阿霉素（FEPI）腹腔化疗治疗肝癌的疗效。方法将35只H22腹水型肝癌荷瘤小鼠分为7组,每组5只,分别予空白微球,生理盐水,低、中、高剂量载药微球（分别含EPI 9、18、36 mg/kg）,FEPI（9 mg/kg）和EPI-PLA-MS＋FEPI（各含EPI 4.5 mg/kg）,经腹腔注射给药,计算动物生命延长率。结果EPI-PLA-MS能有效延长荷瘤鼠的生存时间,并呈量效关系,小鼠最大耐受量约为18-36 mg/kg。联合用药组的平均生存时间、中位生存时间和生命延长率均达到最高值,分别为（40.0±16.9）d、33.5 d和222.58%。结论EPI-PLA-MS缓释剂与游离剂型联合腹腔化疗是一种新型、高效的给药方式,可有效治疗肝癌。
Objective To explore the efficacy of intraperitoneally injected epirubicin （ EPI）-loaded poly （d, 1）-lactic acid （PLA） microspheres （MS） alone or combined with free epirubicin （FEPI） in treating hepatocellular carcinoma （HCC） in mice. Methods Mice that were transplanted with H22 ascites HCC were randomized into seven groups, which were intraperitoneally injected with blank microspheres, normal saline, three different doses of mierospheres （9, 18, and 36 mg/kg EPI） , FEPI （9 mg/kg）, and the combination （ microspheres with EPI 4.5 mg/kg ＋ FEPI 4.5 mg/kg）. The survival time of all animals was recorded. The rates of increase in life span of all the treatment groups were calculated. Results EPI-PLA-MS significantly prolonged the survival time of HCC mice in a dose-dependent manner, with a maximal tolerated dose （MTD） of 18 - 36 mg/kg. The combination group had the highest average survival time, median survival time, and rate of increase in life span, which were （40. 0 ± 16.9） days, 33.5 days, and 222.58% , respectively. Conclusion EPI-PLA-MS combined with FEPI is highly effective in treating HCC in mice when intraperitoneally injected.
出处
《中国医学科学院学报》
CAS
CSCD
北大核心
2009年第5期603-606,共4页
Acta Academiae Medicinae Sinicae
基金
厦门市卫生局重点科研项目(20040103)~~
关键词
表阿霉素
缓释剂
肝肿瘤
联合用药
腹腔化疗
epirubicin
sustained-release drug
hepatocellular carcinoma
drug-combination
intraperitoneal chemotherapy
